"2024 was yet another transformative year for BioArctic. With a another billion-krona deal signed with a global pharmaceutical company, major advances for our BrainTransporter™ technology, continued launch of Leqembi® and the Phase 2a study of exidavnemab in Parkinson's disease in full swing, we have entered a new era. We are now a company that has demonstrated the potential of two groundbreaking innovations: our antibodies and our BrainTransporter technology. Together, these innovations create unique opportunities to help patients with neurodegenerative diseases, while contributing to future value creation for BioArctic's shareholders," says Gunilla Osswald, CEO BioArctic.

BioArctic's work for a sustainable future is encapsulated in the concepts of Sustainable innovation and Sustainable business. The sustainability report summarizes and structures the company's sustainability efforts, to increase transparency and fulfill the expectations of our stakeholders.

The Annual Report, which is attached, can also be downloaded from the company's website, www.bioarctic.com (Investors/Financial reports and presentations).

BioArctic will provide an update on the company's strategy and vision for 2030 during a Capital Markets Day on June 2, 2025. The Capital Markets Day will be held at Helio GT30 in Stockholm, Grev Turegatan 30 in Stockholm, and investors, analysts and financial media is welcome to join.

---

This disclosure contains information that BioArctic is obliged to make public pursuant to the Swedish Securities Markets Act. The information was released for public disclosure, through the agency of the contact person below, on April 22, 2025, at 20:00 CET.

For further information, please contact:

Charlotte af Klercker, Senior Director Sustainability and Communications
Telephone: +46 73 515 09 70
E-mail: charlotte.afklercker@bioarctic.com

Anders Martin-Löf, CFO 
Phone: +46 70 683 79 77 
E-mail: anders.martin-lof@bioarctic.com

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For